Agile Therapeutics, Inc. Share Price

Equities

AGRX

US00847L3087

Biotechnology & Medical Research

Market Closed - OTC Markets 19:59:40 26/04/2024 BST 5-day change 1st Jan Change
0.4 USD 0.00% Intraday chart for Agile Therapeutics, Inc. +5.26% -79.49%
Sales 2022 10.88 871.29 Sales 2023 19.59 1.57K Capitalization 4.9M 392M
Net income 2022 -25M -2B Net income 2023 -14M -1.12B EV / Sales 2022 568,219 x
Net cash position 2022 3.04M 243M Net cash position 2023 385K 30.82M EV / Sales 2023 230,324 x
P/E ratio 2022
-0.19 x
P/E ratio 2023
-0.29 x
Employees 19
Yield 2022 *
-
Yield 2023
-
Free-Float 99.56%
More Fundamentals * Assessed data
Dynamic Chart
1 week+5.26%
Current month+17.65%
1 month+8.11%
3 months-74.68%
6 months-77.14%
Current year-79.49%
More quotes
1 week
0.36
Extreme 0.361
0.43
1 month
0.22
Extreme 0.222
0.43
Current year
0.20
Extreme 0.2
1.98
1 year
0.20
Extreme 0.2
6.71
3 years
0.20
Extreme 0.2
3 840.00
5 years
0.20
Extreme 0.2
9 530.40
10 years
0.20
Extreme 0.2
26 380.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 31/01/04
Director of Finance/CFO 57 30/11/10
Chief Tech/Sci/R&D Officer 58 16/08/20
Members of the board TitleAgeSince
Chief Executive Officer 65 31/01/04
Director/Board Member 68 27/07/16
Director/Board Member 67 17/11/14
More insiders
Date Price Change Volume
26/04/24 0.4 0.00% 28,123
25/04/24 0.4 -0.07% 85,721
24/04/24 0.4003 +8.19% 73,534
23/04/24 0.37 -6.09% 94,553
22/04/24 0.394 +3.68% 15,937

Delayed Quote OTC Markets, April 26, 2024 at 07:59 pm

More quotes
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
More about the company